Results 321 to 330 of about 276,897 (341)

Correction: Gut microbiota affects PD-L1 therapy and its mechanism in melanoma. [PDF]

Cancer Immunol Immunother
Liu S, Liu J, Mei Y, Zhang W.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays

American Journal of Surgical Pathology, 2021
Immunotherapy for the treatment of programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic triple negative breast cancer may benefit patients with metaplastic breast cancer (MpBC). Previous study of PD-L1 in MpBC scored tumor cells (TCs), different from Food and Drug Administration-approved scoring methods.
Anne, Grabenstetter, Achim A, Jungbluth, Denise, Frosina, Raza, Hoda, Carlos H, Dos Anjos, Sujata, Patil, Varadan, Sevilimedu, Britta, Weigelt, Jorge S, Reis-Filho, Hong, Zhang, Tiffany, Traina, Mark E, Robson, Edi, Brogi, Hannah Y, Wen   +13 more
openaire   +2 more sources

Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.

Histology and histopathology, 2021
Programmed death-ligand 1 (PD-L1) is an inhibitory transmembrane protein that can prevent autoimmune response. Upregulated PD-L1 serves as a predictive biomarker for patients who may respond well to immune checkpoint therapies. However, variable associations of PD-L1 level with prognoses have been reported.
Bor-Chyuan, Su, Chen-Hung, Ting, Kang-Yun, Lee, Sheng-Ming, Wu, Po-Hao, Feng, Yao-Fei, Chan, Jyh-Yih, Chen   +6 more
openaire   +2 more sources

PD-L1 controls cancer pyroptosis

Nature Cell Biology, 2020
Programmed death ligand-1 (PD-L1) is well known for its role as an immune checkpoint regulator, but little is known about its function in other cellular processes. A study now shows that in tumour cells PD-L1 mediates pyroptosis, an inflammatory form of cell death, by activating the expression of Gasdermine C, ultimately leading to tumour necrosis.
María Teresa Blasco, Roger R. Gomis
openaire   +2 more sources

PD-L1-specific T cells

Cancer Immunology, Immunotherapy, 2016
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Ahmad, Shamaila Munir, Borch, Troels Holz, Hansen, Morten, Andersen, Mads Hald   +3 more
openaire   +3 more sources

������������������������������������������������PD-L1���CD73������������������

2022

openaire   +1 more source

PD-L1 expression in sebaceous carcinomas

Cancer Immunology, Immunotherapy, 2021
Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. Tumoral immune microenvironment characterization is essential for considering immune checkpoint inhibitors as a treatment option.A total of 173 resected SCs were reviewed. Clinical information, lesion size, and location were collected.
Maelle Saliba, Muhammad Shaheen, Rana El Hajj, Fatmeh Abbas, Shaarif Bashir, Umer Nisar Sheikh, Rami Mahfouz, Asif Loya, Ibrahim Khalifeh   +8 more
openaire   +2 more sources

PD-L1 expression in meningiomas

Journal of Clinical Neuroscience, 2018
The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies.
openaire   +2 more sources

The hidden side of PD-L1

Nature Cell Biology, 2020
PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.
Alison Jaccard, Ping-Chih Ho
openaire   +2 more sources